This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Effect of Rosuvastatin on Adenosine Metabolism

This study has been completed.
Sponsor:
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
NCT00554138
First received: November 5, 2007
Last updated: September 22, 2008
Last verified: September 2008
  Purpose
The aim of this study is to show whether rosuvastatin influences adenosine metabolism. Therefore we will determine whether rosuvasatin increases dipyridamole-induced vasodilation by increased adenosine receptor stimulation.

Condition Intervention
Adenosine Metabolism Drug: placebo Drug: rosuvastatin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • forearm vasodilatory response to dipyridamole [ Time Frame: 7 days ]

Secondary Outcome Measures:
  • lipid profile [ Time Frame: 7-10 days ]

Enrollment: 24
Study Start Date: November 2007
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1 Drug: placebo
1 dd for 7-10 days
Experimental: 2 Drug: rosuvastatin
1 dd 20 mg for 7-10 days

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • age 18 - 50 years
  • Signed informed consent

Exclusion Criteria:

  • hypertension
  • hypercholesterolemia
  • diabetes Mellitus
  • alanine aminotransferase > 90 U/L
  • creatinine Kinase > 440 U/L
  • cardiovascular disease
  • GFR < 80 ml/min
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00554138

Locations
Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500 HB
Sponsors and Collaborators
Radboud University
Investigators
Study Director: Gerard Rongen, MD, PhD Radboud University Medical Centre Dep. Pharmacology-Toxicology
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: G.A. Rongen, Radboud University Nijmegen Medical Centre
ClinicalTrials.gov Identifier: NCT00554138     History of Changes
Other Study ID Numbers: Rosudip01
Study First Received: November 5, 2007
Last Updated: September 22, 2008

Keywords provided by Radboud University:
rosuvastatin
dipyridamole
caffeine

Additional relevant MeSH terms:
Adenosine
Dipyridamole
Rosuvastatin Calcium
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Lipid Regulating Agents

ClinicalTrials.gov processed this record on June 28, 2017